Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Retained Earnings (2019 - 2025)

Keros Therapeutics filings provide 7 years of Retained Earnings readings, the most recent being -$481.8 million for Q4 2025.

  • On a quarterly basis, Retained Earnings rose 15.3% to -$481.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$481.8 million, a 15.3% increase, with the full-year FY2025 number at -$481.8 million, up 15.3% from a year prior.
  • Retained Earnings hit -$481.8 million in Q4 2025 for Keros Therapeutics, down from -$458.3 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$80.9 million in Q1 2021 to a low of -$568.8 million in Q4 2024.
  • Median Retained Earnings over the past 5 years was -$321.5 million (2023), compared with a mean of -$312.7 million.
  • Biggest five-year swings in Retained Earnings: plummeted 156.47% in 2021 and later rose 15.3% in 2025.
  • Keros Therapeutics' Retained Earnings stood at -$123.8 million in 2021, then tumbled by 84.59% to -$228.4 million in 2022, then crashed by 66.97% to -$381.4 million in 2023, then plummeted by 49.12% to -$568.8 million in 2024, then grew by 15.3% to -$481.8 million in 2025.
  • The last three reported values for Retained Earnings were -$481.8 million (Q4 2025), -$458.3 million (Q3 2025), and -$451.0 million (Q2 2025) per Business Quant data.